Advertisement

 

 

Clinically significant mutations in HIV-infected patients with lung adenocarcinoma.

Clinically significant mutations in HIV-infected patients with lung adenocarcinoma.
Author Information (click to view)

Thaler J, Sigel C, Beasley MB, Wisnivesky J, Crothers K, Bauml J, Hysell K, Emu B, Borsu L, Sigel K,


Thaler J, Sigel C, Beasley MB, Wisnivesky J, Crothers K, Bauml J, Hysell K, Emu B, Borsu L, Sigel K, (click to view)

Thaler J, Sigel C, Beasley MB, Wisnivesky J, Crothers K, Bauml J, Hysell K, Emu B, Borsu L, Sigel K,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

British journal of cancer 2017 09 21117(9) 1392-1395 doi 10.1038/bjc.2017.333

Abstract
BACKGROUND
Lung cancer is a major cause of death in HIV-infected (HIV+) persons. In this study, we compared the prevalence of tumour EGFR and KRAS mutations in a cohort of lung adenocarcinoma patients by HIV status.

METHODS
We collected data from 55 HIV+ patients with lung adenocarcinoma matched to 136 uninfected comparators. We compared the prevalence of EGFR and KRAS mutations by HIV status. We then compared survival by HIV status and by cancer mutation status among HIV+ subjects.

RESULTS
Presence of KRAS and EGFR genetic alterations did not vary by HIV status (all P>0.1). There was no difference in overall survival by HIV status or by mutation status among HIV+ subjects.

CONCLUSIONS
We found no major differences in the prevalence of EGFR or KRAS lung adenocarcinoma mutations by HIV status, suggesting that mutational testing should be conducted similarly regardless of the HIV status.

Submit a Comment

Your email address will not be published. Required fields are marked *

19 − 12 =

[ HIDE/SHOW ]